Bandingkan Harga & Kinerja KMI Wire Cable Tbk (KBLI) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan KMI Wire Cable Tbk dan Organon Pharma Indonesia Tbk.: KMI Wire Cable Tbk diperdagangkan di Rp340 (kapitalisasi pasar 1,34 T, volume 24 jam 650,3 rb), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: KMI Wire Cable Tbk jauh lebih besar — sekitar 12,8× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| KBLI | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 1,34 T | 104,4 M |
Volume | 650,3 rb | — |
Lot | 6,5 rb | — |
Perputaran | 218,33 jt | — |
Harga Rata-rata | 335,73 | — |
Nilai Transaksi | 218,33 jt | — |
Harga Ekuilibrium Indikatif | 340 | — |
Volume Ekuilibrium Indikatif | 136 | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang KMI Wire Cable Tbk
PT KMI Wire and Cable Tbk (the Company) formerly PT. GT Kabel Indonesia is one of the largest telecommunications and power cable producer. It is owned 53% by Gadjah Tunggal Group. It was established in 1972 by Electro GmbH of Germany (today known as Alcatel Kabelmetal) and PT Gunung Ngadeg Djaya.The Company was established wtihin the framework of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970, based on deed No. 42 dated January 19, 1972 of Djojo Muljadi, SH, notary in Jakarta
Selengkapnya di halaman KBLI →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
